Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:51 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis
NCT01016262 · Forest Laboratories · PHASE3 · terminated · last registry update 2019-08-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The decision was taken solely for business/administrative reasons, no safety considerations entered into this. Ongoing randomized patients to complete.” | – | Registry record, Forest Laboratories |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALOX5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-14Results posted on the registry: Holy Stone Healthcare Co., Ltd, High dose + Low dose (NCT02493712)
- 2020-08-10Results posted on the registry: Sanofi, SARILUMAB + Azathioprine (NCT03449758)
- 2020-07-22Results posted on the registry: Hutchison Medipharma Limited, HMPL-004 low dose + Placebo (NCT00659802)
- 2020-06-17Phase 3 first posted: University Hospital, Ghent, week 24 + week 36 (NCT04435288)
- 2020-03-23Results posted on the registry: National Cancer Institute (NCI), Aspirin + Zileuton (NCT02348203)
- 2020-01-18Results posted on the registry: Shire, MMX Mesalamine/Mesalazine (Low Dose) + MMX Mesalamine/Mesalazine (High Dose) (NCT02093663)
- 2020-01-18Also stopped (terminated): VSL Pharmaceuticals, Mesalamine + Placebo (NCT03415711)
- 2019-11-18Also stopped (terminated): University of Minnesota, Zileuton + Placebo (NCT00493974)
- 2019-11-01Results posted on the registry: Bausch Health Americas, Inc., Encapsulated Mesalamine Granules (eMG) (NCT00326209)
- 2019-10-15Results posted on the registry: Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-10-15Also stopped (terminated): Endeavor Health, Rectal dialysis (NCT04032652)
- 2019-09-06Results posted on the registry: Bausch Health Americas, Inc., Budesonide MMX® + Placebo (NCT01532648)
- 2019-08-28Results posted on the registry: Connecticut Children's Medical Center, Mesalazine + IV Corticosteroid (NCT01536535)
- 2019-05-14Results posted on the registry: University of Nebraska, Leflunomide + Methotrexate-Sulfasalazine-Hydroxychloroquine (NCT00579878)
- 2019-04-18Also stopped (terminated): Christoph Gasche, mesalamine 2400 MG (5-ASA) + mesalamine 1200 MG (NCT03070574)
- 2019-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, Meclofenamic acid + Pentosan polysulfate sodium (NCT02930005)
- 2019-01-29Also stopped (terminated): Annette Langseder, Asacol (NCT00349388)
- 2019-01-15Phase 3 first posted: Guangzhou First People's Hospital, 5-Aminosalicylic acid(5-ASA) and/or Prednisone (NCT03804931)
- 2018-12-10Results posted on the registry: P. Verschueren, Methotrexate + Sulfasalazine (NCT01172639)
- 2018-11-13Results posted on the registry: Hoffmann-La Roche, Azathioprine + Chloroquine (NCT01941095)
- 2018-10-23Phase 3 first posted: Dayanand Medical College and Hospital, Fecal Microbiota Transplantation + Mesalamine Granules (NCT03716388)
- 2018-09-06Phase 3 first posted: Astellas Pharma China, Inc., Peficitinib + Plaebo (NCT03660059)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision